Flagship Harbor Advisors’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-1,279
Closed -$314K 644
2022
Q3
$314K Sell
1,279
-20
-2% -$5.4K 0.04% 426
2022
Q2
$322K Buy
1,299
+208
+19% +$56.1K 0.04% 439
2022
Q1
$361K Sell
1,091
-60
-5% -$18.5K 0.03% 434
2021
Q4
$413K Buy
1,151
+414
+56% +$140K 0.04% 409
2021
Q3
$230K Hold
737
0.02% 563
2021
Q2
$230K Buy
737
+23
+3% +$7.06K 0.02% 564
2021
Q1
$228K Buy
714
+60
+9% +$19.2K 0.03% 568
2020
Q4
$212K Buy
654
+64
+11% +$17.7K 0.03% 525
2020
Q3
$163K Sell
590
-32
-5% -$9.22K 0.02% 519
2020
Q2
$150K Sell
622
-433
-41% -$86.9K 0.02% 529
2020
Q1
$153K Sell
1,055
-208
-16% -$34.5K 0.03% 445
2019
Q4
$215K Sell
1,263
-657
-34% -$122K 0.04% 422
2019
Q3
$341K Buy
1,920
+128
+7% +$27.7K 0.07% 285
2019
Q2
$466K Sell
1,792
-138
-7% -$36.6K 0.1% 215
2019
Q1
$551K Buy
1,930
+157
+9% +$52.2K 0.11% 197
2018
Q4
$576K Sell
1,773
-342
-16% -$119K 0.14% 160
2018
Q3
$940K Buy
2,115
+250
+13% +$98.5K 0.17% 134
2018
Q2
$762K Buy
1,865
+618
+50% +$224K 0.15% 148
2018
Q1
$350K Buy
1,247
+72
+6% +$18.2K 0.1% 222
2017
Q4
$242K Buy
+1,175
New +$219K 0.07% 297

Other funds holding ABMD

Flagship Harbor Advisors's ABMD Position: Q4 2022 in Review

Flagship Harbor Advisors sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 1,279 shares — an estimated $314K sold.

Flagship Harbor Advisors first reported a position in ABMD in Q4 2017 and held it in 20 quarters. The position peaked at $940K in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Flagship Harbor Advisors reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Flagship Harbor Advisors sold 1,279 Abiomed Inc shares in Q4 2022, an estimated $314K.
  • Flagship Harbor Advisors first reported a position in Abiomed Inc in Q4 2017 and held it in 20 quarters.
  • Flagship Harbor Advisors's Abiomed Inc position peaked at $940K in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Flagship Harbor Advisors's 13F filing for Q4 2022, filed 13 Jan 2023.